MannKind rewarded for positive Afrezza data with $40M financing

John Carroll

's take on interim Phase III for its inhaled insulin has a big sweetener tied to it. The Valencia, CA-based MannKind has picked up a much-needed $ 40 million from Deerfield as a result of the data readout, the second of four tranches slated to provide MannKind with $ 160 million total.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS